factor VIII inhibitor bypassing activity: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
factor VIII inhibitor bypassing activity: clinical details
Prescribing considerations
- Initiate and monitor treatment through a clinician experienced in coagulation disorders.
- Assess concurrent emicizumab, recombinant activated factor VII or systemic antifibrinolytic use.
- Consider thrombosis risk factors, including coronary or liver disease, previous thrombosis, immobilisation, sepsis and the postoperative state.
- Account for sodium content where dietary sodium restriction is important.
- Record the product name and batch number for traceability.
- For repeated plasma-derived treatment, consider hepatitis A and B vaccination and discuss residual transmissible-agent risk.
Contraindications and cautions
- Where therapeutic alternatives are available: hypersensitivity to the active substance or excipients.
- Where therapeutic alternatives are available: disseminated intravascular coagulation.
- Where therapeutic alternatives are available: acute thrombosis or embolism, including myocardial infarction.
Monitoring
- Assess clinical haemostatic response rather than attempting to normalise routine coagulation tests.
- Monitor for hypersensitivity, disseminated intravascular coagulation, acute coronary ischaemia and other thrombotic or thromboembolic events.
- Check platelet count if clinical response is inadequate.
- Be aware that aPTT, whole-blood clotting time and thromboelastography correlate poorly with efficacy.
- Passively transferred antibodies may interfere with hepatitis B serology and red-cell antibody testing.
Clinical pharmacology
An activated prothrombin complex concentrate containing prothrombin-complex zymogens and small amounts of activated factors. Its haemostatic action is principally attributed to enhanced thrombin generation involving factor Xa and prothrombin; conventional pharmacokinetic characterisation is inconclusive.
Formulation and product differences
- Powder supplied with water for injections and a transfer device for reconstitution before intravenous infusion.
- Vial presentations differ in total factor VIII inhibitor bypassing activity, plasma-protein content, solvent volume and sodium content.
- Not all authorised pack sizes may be marketed.
factor VIII inhibitor bypassing activity interactions
The haemophilia team should review all haemostatic treatments because some combinations may increase clotting complications.
Systemic antifibrinolytics, including tranexamic acid and aminocaproic acid
Use close to this treatment may increase thromboembolic risk, so timing must be directed by a specialist.
Recombinant activated factor VII
Combined or sequential use may increase thromboembolic risk.
Emicizumab
Serious thrombotic microangiopathy and thrombotic complications have occurred with intensive combined exposure. Specialist assessment and close monitoring are required.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.